News
CRDL
1.690
-1.17%
-0.020
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT), Tango Therapeutics (TNGX) and Cardiol Therapeutics (CRDL)
TipRanks · 4d ago
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
Benzinga · 5d ago
Cardiol Therapeutics Expands Phase III MAVERIC Trial After Early Enrollment Milestone
TipRanks · 5d ago
Cardiol Therapeutics achieves enrollment target for Phase III MAVERIC trial
TipRanks · 5d ago
Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis
Benzinga · 5d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiol Therapeutics (CRDL), Tyra Bioscience (TYRA) and Alibaba Health Information Technology (OtherALBHF)
TipRanks · 6d ago
Weekly Report: what happened at CRDL last week (0914-0918)?
Weekly Report · 09/21 10:01
Cardiol Therapeutics raises over US$7M through warrant exercises
Seeking Alpha · 09/16 12:00
Cardiol Therapeutics Bolsters Cash Runway with $7 Million Warrant Exercise Ahead of Phase III Data
TipRanks · 09/16 11:52
Cardiol Therapeutics receives over $7M in proceeds from warrant exercise
TipRanks · 09/16 11:30
Cardiol Therapeutics Bolsters Governance With Updated Code of Conduct Filing
TipRanks · 09/15 10:30
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
NASDAQ · 09/14 13:30
Weekly Report: what happened at CRDL last week (0907-0911)?
Weekly Report · 09/14 10:05
Cardiol Therapeutics: Q1 2027 Readout Will Be Make-Or-Break For Maveric
Seeking Alpha · 09/12 13:15
At a glance: stocks gapping up premarket
Seeking Alpha · 09/11 11:08
Cardiol Therapeutics Details Long-Term Manufacturing and Development Agreements in September SEC Filing
TipRanks · 09/11 10:27
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus After OSC Review
TipRanks · 09/10 21:57
Cardiol Therapeutics files $150M preliminary base shelf prospectus
TipRanks · 09/10 21:05
Cardiol Therapeutics files US$150M base shelf prospectus
Seeking Alpha · 09/10 21:03
Cardiol Therapeutics Files $150M Base Shelf Prospectus, Enabling Future Offerings Of Shares, Debt, Warrants And Other Securities
Benzinga · 09/10 21:02
More
Webull provides a variety of real-time CRDL stock news. You can receive the latest news about Cardiol Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About CRDL
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.